Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This review explores oncofetal chondroitin sulfate (ofCS) as a revolutionary AML target. Unlike traditional antigens, ofCS is absent in normal bone marrow, allowing antibody-drug conjugates to eliminate leukemia cells with minimal hematotox
This review evaluates a novel open-source extraction pipeline designed to standardize and automate the processing of complex HSCT registry data, enhancing reproducibility and precision in clinical outcomes research.
This clinical review examines the management of treatment-emergent adverse events (TEAEs) in patients with chronic myeloid leukemia. It highlights strategies for dose optimization and proactive toxicity management to balance molecular respo
Emerging data from UK clinical trials indicate that while high genomic complexity (HGC) correlates with poor outcomes in CLL, it often serves as a surrogate for other established high-risk markers like TP53 status and telomere length.
A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.
A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populat
The 15-year follow-up of the SWOG S0016 trial demonstrates that approximately 42% of patients with advanced follicular lymphoma may be cured with initial CHOP-based chemoimmunotherapy, with relapse rates dropping significantly after 15 year
Researchers have identified that a specific somatic hypermutation (K31E) in the IGLV3-21*02/03 allele triggers VITT by causing antibodies intended for adenoviral protein pVII to cross-react with Platelet Factor 4 (PF4), explaining the patho
A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.
A retrospective study across 29 European countries reveals that mortality from haemophagocytic lymphohistiocytosis (HLH) increased significantly between 2011 and 2021, with notable bimodal age peaks and geographical disparities suggesting w
The updated CARTITUDE-4 analysis demonstrates that cilta-cel significantly improves overall survival and progression-free survival compared to standard therapies in lenalidomide-refractory multiple myeloma patients after the first relapse,
A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradicati
The STRIDES trial, the largest of its kind, demonstrates that isotonic drinks, extended rest, modified muscle tension, and psychosocial support do not significantly reduce vasovagal reactions in blood donors compared to existing UK standard
A phase 2 trial demonstrates that combining cabozantinib with temozolomide provides significant progression-free survival benefits for patients with advanced leiomyosarcoma, achieving a 74% 12-week PFS rate with a manageable safety profile,
A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i
The RESMAIN trial demonstrates that resminostat maintenance therapy doubles median progression-free survival in patients with advanced mycosis fungoides or Sézary syndrome, offering a potential new standard for managing patients who have ac
A molecular re-evaluation of the pivotal CPX-351 phase 3 trial reveals that its survival benefit is selectively confined to patients with myelodysplasia-related mutations (AML-MR), with no significant advantage over standard 7+3 induction i
The CART19-BE-02 phase 2 trial demonstrates that varnimcabtagene autoleucel, utilizing a unique fractionated dose escalation strategy, achieves an 84.4% MRD-negative complete response rate in adults with relapsed or refractory B-ALL while s
A newly developed prognostic model integrates mutational and cytogenetic data to accurately predict survival in AML patients receiving HMA/VEN therapy, offering superior risk stratification into low-, intermediate-, and high-risk categories
A multicenter cohort study of 8,874 pediatric patients reveals that most prophylactic platelet transfusions occur above recommended thresholds. Factors such as pathogen reduction, additive solutions, and donor age significantly lower posttr
Open language-specific specialty feeds and department pages.